Reported about 7 hours ago
Novavax, a COVID-19 vaccine manufacturer, reported a sharp decline in fourth-quarter revenues, dropping from $291 million to $88 million, and plans to transition from solely vaccine production to partnering with larger pharmaceutical companies and licensing its technology. The company aims to reduce its annual expenses significantly and is also shifting focus beyond respiratory viruses, exploring new therapeutic applications.
Source: YAHOO